GlassScriptPhysician profile
Ferrol J Lee
NPI 1356312151
$3,553.86
in general payments reported to CMS, 2019-2025
31 companies · $58.61 in 2025
The $58.61 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $328 · 2021: $513 · 2022: $758 · 2023: $529 · 2024: $958 · 2025: $58.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,545.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $574.69 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $379.14 | 2019-2024 | |
| Dexcom, INC. | $331.46 | 2021-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $244.15 | 2020-2024 | Ozempic, Rybelsus |
| Tandem Diabetes Care, INC. | $242.03 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $181.43 | 2019-2024 | Farxiga |
| Xeris Pharmaceuticals, INC. | $174.64 | 2020-2024 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.18 | 2020-2022 | |
| Medtronic, INC. | $148.08 | 2021-2024 | Minimed 780g |
| Insulet Corporation | $136.59 | 2019-2023 | Omnipod |
| Ascensia Diabetes Care US INC. | $114.00 | 2021-2024 | |
| Genzyme Corporation | $110.00 | 2019 | |
| Amgen INC. | $97.83 | 2020-2024 | Prolia, Evenity |
| Senseonics, Incorporated | $79.00 | 2019 | |
| Cequr Corporation | $75.58 | 2023-2025 | Cequr Simplicity |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $59.03 | 2023-2024 | Crysvita |
| Beta Bionics, INC. | $51.39 | 2023-2024 | Ilet Bionic Pancreas |
| Amneal Pharmaceuticals LLC | $51.27 | 2024 | Unithroid |
| Recordati_rare_diseases_inc. | $46.78 | 2024 | Signifor Lar, Isturisa |
| Medtronic Minimed, INC. | $44.69 | 2020 | |
| Abbvie INC. | $37.74 | 2023-2024 | |
| Corcept Therapeutics | $34.67 | 2023 | Korlym |
| Radius Health, INC. | $34.36 | 2023 | Tymlos |
| Valeritas, INC. | $33.69 | 2019 | |
| Companion Medical, INC. | $20.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.11 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.42 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $15.73 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $15.72 | 2020 | |
| Pfizer INC. | $13.57 | 2021 | |
| Becton, Dickinson and Company | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ferrol Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.